PharmaLundensis
0.20 SEK
-6.10 %
Less than 1K followers
PHAL
Spotlight Stock Market
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-6.10 %
-13.04 %
-18.70 %
-41.86 %
-15.25 %
-78.68 %
-48.34 %
-77.02 %
-93.90 %
PharmaLundensis is a research company. The company's main focus is on the treatment of serious lung diseases. Diseases that the company specializes in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced pulmonary failure. In addition to its main business, technical systems for handling drug emissions are developed. PharmaLundensis has its headquarters in Lund.
Read moreMarket cap
12.86M SEK
Turnover
2.41K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
21/5
2026
Interim report Q1'26
20/8
2026
Interim report Q2'26
19/11
2026
Interim report Q3'26
All
Press releases
ShowingAll content types
PharmaLundensis: Publicering av emissionshandlingar och start av teckningstid
PharmaLundensis: BOKSLUTSKOMMUNIKÉ 2025-01-01 till 2025-12-31
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools